BMC Infectious Diseases | |
Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial | |
Research Article | |
Ziad A. Memish1  Devayani Kolhe2  Jacqueline M. Miller3  Marie Van der Wielen4  Dominique Boutriau4  Cecilia Montalban5  Charissa Fay Corazon Borja-Tabora6  | |
[1] College of Medicine, Alfaisal University, Al Zahrawi Street, Al Maather, Al Takhassusi Rd, 11533, Riyadh, Saudi Arabia;GSK Pharmaceuticals Limited, Embassy Links, #5, SRT Road, 560052, Bangalore, India;GSK Vaccines, 2301 Renaissance Blvd, 19406, King of Prussia, PA, USA;GSK Vaccines, Avenue Fleming 20, B- 1300, Wavre, Belgium;Philippine General Hospital Manila, Taft Avenue, Ermita, 1000, Manila, Metro Manila, Philippines;Research Institute for Tropical Medicine, Corporate Ave, 1781, Muntinlupa City, Metro Manila, Philippines; | |
关键词: Quadrivalent meningococcal conjugate vaccine; Bactericidal antibody; Antibody persistence; Safety; | |
DOI : 10.1186/s12879-015-1138-y | |
received in 2015-02-12, accepted in 2015-09-21, 发布年份 2015 | |
来源: Springer | |
【 摘 要 】
BackgroundLong-term protection against meningococcal disease is associated with persistence of post-vaccination antibodies at protective levels. We evaluated the bactericidal antibody persistence and safety of the quadrivalent meningococcal serogroups A, C, W and Y tetanus-toxoid conjugate vaccine (MenACWY-TT) and the meningococcal polysaccharide serogroups A, C, W, and Y vaccine (MenACWY-PS) up to 5 years post-vaccination.MethodsThis phase IIb, open, randomized, controlled study conducted in the Philippines and Saudi Arabia consisted of a vaccination phase and a long-term persistence phase. Healthy adolescents and adults aged 11–55 years were randomized (3:1) to receive a single dose of MenACWY-TT (ACWY-TT group) or MenACWY-PS (Men-PS group). Primary and persistence results up to 3 years post-vaccination have been previously reported. Antibody responses against meningococcal serogroups A, C, W, and Y were assessed by a serum bactericidal antibody assay using rabbit complement (rSBA, cut-off titers 1:8 and 1:128) at Year 4 and Year 5 post-vaccination. Vaccine-related serious adverse events (SAEs) and cases of meningococcal disease were assessed up to Year 5.ResultsOf the 500 vaccinated participants, 404 returned for the Year 5 study visit (Total Cohort Year 5). For the Total Cohort Year 5, 71.6–90.0 and 64.9–86.3 % of MenACWY-TT recipients had rSBA titers ≥1:8 and ≥1:128, respectively, compared to 24.8–74.3 and 21.0–68.6 % of MenACWY-PS recipients. The rSBA geometric mean titers (GMTs) remained above the pre-vaccination levels in both treatment groups. Exploratory analyses suggested that both rSBA GMTs as well as the percentages of participants with rSBA titers above the cut-offs were higher in the ACWY-TT than in the Men-PS group for serogroups A, W and Y, with no apparent difference for MenC. No SAEs related to vaccination or cases of meningococcal disease were reported up to Year 5.ConclusionThese results suggest that a single dose of MenACWY-TT could protect at least 72 % of vaccinated adolescents and adults against meningococcal disease at least 5 years post-vaccination.Trial registrationClinicalTrials.gov NCT00356369
【 授权许可】
CC BY
© Borja-Tabora et al. 2015
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202311093365257ZK.pdf | 952KB | download |
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]
- [40]
- [41]
- [42]
- [43]
- [44]
- [45]
- [46]
- [47]
- [48]
- [49]
- [50]
- [51]
- [52]
- [53]
- [54]
- [55]
- [56]